On 4/5/2017, Shares of Edison International (NYSE:EIX) closed at $80.59 in last trading day. After noting the initial trading entry at $79.95, it reached to a day’s high of $80.68 and moved to a day’s low of $79.62. The recent daily volume was 1.61 million as contrast to it’s an average volume of 1.73 million.
The last close of the Edison International stock reflects that it traded up +2.00% from its 50-day moving average of $79.01. The stock traded above +9.78% to its 200-day MA of $73.41. Furthermore, it moved lower -0.91% from its 52-week high of $81.33 and +19.50% up from $67.44, which is 52-week low of the stock.
During the last month, Edison International’s (EIX) has changed 2.38% and performed 16.97% over the last 6 months. The mean rating score for this stock is at 2.20. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 1.15% in recent month and observed Weekly Volatility of 1.04%.
Edison International, through its subsidiaries, engages in the generation, transmission, and distribution of electricity in the United States. The company generates electricity through hydroelectric, diesel, natural gas, nuclear, and photovoltaic sources. It supplies electricity primarily to commercial, residential, industrial, agricultural, and other customers, as well as public authorities through transmission and distribution networks. The company’s transmission facilities consist of lines ranging from 33 kV to 500 kV and substations; and distribution system comprises approximately 53,000 line miles of overhead lines, 38,000 line miles of underground lines, and approximately 800 distribution substations located in California. It serves approximately 5 million customers. Edison International was incorporated in 1987 and is based in Rosemead, California.
Genocea Biosciences, Inc. (NASDAQ:GNCA) finalized the last transaction at value of $5.87, with a daily change of +3.53% or +0.20 points. The company maintained volume of 200.24 thousand shares. In past trading day, the stock hit the maximum price of $6.04 and touched to minimum value of $5.58. It has a market cap of $ 166.97M.
As of last trade close, the stock is trading downside -18.47% from its one year high of $7.20 and moved +78.96% upward from $3.28, which is one year low of the stock.
The stock traded above +8.93% from its 50-day moving average of $5.39. Furthermore, the stock moved up +27.75% to its 200-day MA of $ 4.59.
Genocea Biosciences, Inc.’s (GNCA) moved with shift of -1.18% in the past week. Over the last three months, the shares of the company have changed 29.30% and performed 31.61% over the last six months. The stock currently has Monthly Volatility of 6.36% and Weekly Volatility of 6.64%.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design vaccines and immunotherapies that act through T cell immune responses. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. The company is also developing GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and GEN-007 that is in research stage for the treatment of Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.